BioCardia, Inc. is facing a significant challenge as it received a notice from Nasdaq regarding its non-compliance with listing requirements. The company reported stockholders' equity of only $835,000, falling short of the $2.5 million minimum required for continued listing on the Nasdaq Capital Market. This situation necessitates immediate action from the company, as it must submit a plan to regain compliance by January 4, 2027.
The notice, issued on November 20, 2026, does not impact the current trading of BioCardia's common stock, which will continue to be listed under the ticker symbol “BCDA.” However, the company’s future on the exchange hinges on its ability to present a viable plan to Nasdaq that demonstrates how it intends to meet the required equity threshold.
Background
BioCardia, Inc. operates within the biological products sector, specifically under the SIC code 2836, which encompasses biological products excluding diagnostic substances. The company is listed on the Nasdaq Capital Market and is categorized as a non-accelerated filer and a smaller reporting company. Its recent filings include an 8-K on November 12, 2026, and a 10-Q on the same date, indicating ongoing financial disclosures and updates.
What the Filing Says
The filing states, “On November 20, 2026, BioCardia, Inc. received written notice from The Nasdaq Stock Market LLC notifying the Company that, based on the Company’s stockholders’ equity of $835,000 as of September 30, 2026, it is no longer in compliance with the minimum stockholders’ equity requirement of $2.5 million for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1).” Furthermore, it mentions that the company has until January 4, 2027, to submit a compliance plan.
Impact
This situation may affect BioCardia’s shareholders and employees, as well as potential investors who may view the company’s financial stability as a risk. If Nasdaq does not accept the compliance plan, the company could face a hearing where it would present its case to a Nasdaq Hearings Panel. The outcome of this process could significantly influence the company's future operations and market perception.
What’s Next
BioCardia intends to submit a plan to Nasdaq to regain compliance with its listing requirements. The filing does not specify what happens next if the plan is accepted or rejected, but it does indicate that Nasdaq will evaluate the plan based on various factors, including the company’s past compliance history and overall financial condition.
Read Next
Alps Group Regains Compliance with Nasdaq Listing Standards
Ainos, Inc. Receives Nasdaq Delisting Notice Over Equity
Compass Therapeutics Receives Nasdaq Deficiency Notice
60 Degrees Pharmaceuticals Faces Nasdaq Delisting Risk
Biofrontera Inc. Faces Nasdaq Delisting Due to Low Stock Price
Senti Biosciences dismisses KPMG, appoints new auditor KNAV










